Industry News

Aduro Biotech, Inc. today highlighted two posters presented at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York. The preclinical data demonstrate positive changes in the tumor microenvironment and induction of a tumor-specific immune response by Aduro’ s LADD and STING Pathway Activator immunotherapy platform technologies. Importantly, adding a PD-1 blockade to either immunotherapy regimen..."/>
Aduro Biotech Presents Encouraging Preclinical Data Showing Combination Synergy of its Immunotherapy and Checkpoint Inhibitors to Increase Antitumor Efficacy
UnitedHealth Group, has earned Frost& Sullivan's Company of the Year Award for the population health management market. While more than 100 health care IT companies comprise the U.S. population health management market today, most serve only specific PHM segments. Optum serves all category participants– ranging from health care providers to commercial health plans– and was..."/>
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
Sorrento Therapeutics, Inc., has filed the Effectiveness and Target Animal Safety major technical sections of the New Animal Drug Application for the control of pain associated with bone cancer in dogs. ARK was granted a Minor Use/ Minor Species Drug Designation for ARK-001, a proprietary formulation containing the active ingredient Resiniferatoxin in June 2015. Under the MUMS designation, ARK seeks the..."/>
ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major Technical Sections of a New Animal Drug Application
Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced today that the Impella 2.5 and Impella 5.0 heart pumps received Pharmaceuticals and Medical Devices Agency approval from the Japanese Ministry of Health, Labor& Welfare for the treatment of drug-resistant acute heart failure.. With this approval, these are the first and only percutaneous temporary ventricular support devices that are PMDA-approved in Japan..."/>
Abiomed Impella 2.5™and Impella 5.0™ Heart Pumps Receive Regulatory Approval From Japan Ministry of Health, Labor & Welfare
Nektar Therapeutics announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at 9:00 a.m. Eastern Time/ 6:00 a.m. Pacific Time on Tuesday, September 27, 2016. A live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website at..."/>
Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb
Incyte Corporation today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi ®, has been included as a recommended treatment in the latest National Comprehensive Cancer Network ® Clinical Practice Guidelines in Oncology for myelofibrosis. “Jakafi is the first FDA-approved treatment for patients with..."/>
NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentations of new pre-clinical data on the mechanism of action supporting selective targeting of single point mutations. Also, data was presented on 3 GA targeting the NLRP3 gene for the treatment of..."/>
Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Meridian Bioscience said on Monday that it has amended its agreement with Eiken Chemical Co Ltd Japan to license the latter's' LAMP' technology for the expanded areas of animal, food and water testing. The LAMP technology, developed at EIKEN in 1998, is a core technology being exploited to develop a range of products. The LAMP technology is a leading nucleic acid amplification method that is simple to perform, rapid, highly specific and performed at a single..."/>
Meridian amends molecular test technology license agreement with Eiken Chemical Co to include food or water
Cumberland Pharmaceuticals reported on Monday that it has started promoting Ethyol for Injection in the US oncology market. The company said the US launch represents an important milestone in ensuring patients have the best opportunity to be treated with Ethyol, should they need it. In preparation with Ethyol's market launch, the company has completed training its sales and medical organisation, stocked the product at wholesalers serving..."/>
Cumberland Pharmaceuticals promotes Ethyol in support of oncology patients in the US
Chembio Diagnostics reported on Monday the receipt of US Department of Agriculture's USD600, 000 grant to develop a POC diagnostic test for bovine tuberculosis under the Small Business Innovation Research Program of the National Institute of Food and Agriculture. As part of the two-year grant, the company will use its patented DPP technology to undertake to develop a simple, rapid, accurate and cost-effective test for bovine TB in cattle."/>
Chembio receives USD600,000 US Department of Agriculture award to develop point-of-care diagnostic test for bovine tuberculosis
Communique from Oasmia's Annual General Meeting 2016
Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in Clinical..."/>
New Study Underscores Ability of iStent® Trabecular Micro-Bypass Stent to Achieve Sustained Reductions in IOP and Medication Use in Glaucoma Patients Undergoing Cataract Surgery
ProNAi Therapeutics, Inc., a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an..."/>
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, today announces it has received Rare Pediatric Disease designation from the US Food and Drug Administration for ezutromid in the treatment of DMD. As a utrophin modulator, ezutromid has potential as a disease-modifying treatment for all patients with the fatal muscle wasting..."/>
Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
pSivida Corp., a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the appointment of Jay S. Duker, M.D, to the Company’ s Board of Directors. Duker is the Director of the New England Eye Center and Professor and Chairman of Ophthalmology at the Tufts Medical Center and the Tufts University School of Medicine.. Jay Duker is a recognized international expert in the treatment of diseases of the..."/>
PSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the initiation of the Phase 3 IAP312 study of Zalviso ®, an investigational product candidate being developed for the management of moderate-to-severe acute pain in adult patients in a hospital setting."/>
AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain
Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine, today announced that the first patient with incomplete AIS-B cervical spinal cord injury was successfully dosed with 10 million cells of AST-OPC1 in the SCiSTAR clinical trial at Shepherd Center in Atlanta. The company recently received FDA clearance to expand the study into this additional patient population based on the..."/>
Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population
Accuray Incorporated announced today that data from a prospective, 21 center study showed 97 percent of low- and intermediate-risk prostate cancer patients had excellent cancer control five years after receiving stereotactic body radiation therapy administered with the CyberKnife ® System. The treatment was extremely well-tolerated; serious side effects were uncommon after more than five years of follow-up."/>
Prospective, Multi-Institutional Study Shows Five Treatments with the CyberKnife® System Provide Excellent Disease Control for Prostate Cancer Patients
Hill-Rom Holdings, Inc.. The combination creates the most comprehensive perinatal safety platform available, and marks a new era in obstetric solutions. Users of both the PeriGen PeriCALM ® and WatchChild..."/>
PeriGen and WatchChild Combine Forces
ProNAi Therapeutics, Inc., a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained..."/>
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology541 Articles
Consumer Discretionary478 Articles
Financials307 Articles
Industrials295 Articles
Health Care265 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at